febuxostat (Adenuric) for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).
June 2016 decisions news release The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today published advice accepting four new medicines for routine use by NHSScotland.
